| Title |
Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective
|
|---|---|
| Published in |
ClinicoEconomics and Outcomes Research: CEOR, November 2018
|
| DOI | 10.2147/ceor.s180067 |
| Pubmed ID | |
| Authors |
Dhvani Shah, Nancy A Risebrough, Johnna Perdrizet, Neeraj N Iyer, Cory Gamble, Tam Dang-Tan |
Mendeley readers
The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 51 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 18% |
| Student > Master | 8 | 16% |
| Student > Bachelor | 5 | 10% |
| Other | 3 | 6% |
| Student > Postgraduate | 3 | 6% |
| Other | 6 | 12% |
| Unknown | 17 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 31% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 10% |
| Economics, Econometrics and Finance | 3 | 6% |
| Nursing and Health Professions | 2 | 4% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Other | 4 | 8% |
| Unknown | 19 | 37% |